Samuel D. Rabkin

Oncolytic herpes simplex virus vectors for cancer virotherapy.

Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.

Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.

Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.

Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.

Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.

Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.

Current status of gene therapy for brain tumors.

An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta.

Designing Herpes Viruses as Oncolytics.

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.

Oncolytic herpes simplex virus interactions with the host immune system.

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade.

Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.

Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells.

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.

Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.